Target Indication Insights Why did the type 2 diabetes segment dominate the obesity GLP-1 market
And when I kind of spoke to my MD counterparts, I learned early on that this was more treating symptoms in the pharmaceutical approach rather than something that's treating kind of root cause medicine or underlying drivers
Stopping Safely Some people stop taking medications such as Lexapro and Prozac because of weight gain and other side effects
However, approaches vary: Some employers cover GLP-1s for diabetes only, but exclude them for weight loss unless medically necessary
In RBCs, this hyperoxidation of Prx2 does not occur, as it is counteracted by sulfiredoxin [60, 73]
By addressing multiple drivers of weight gain at once, it can assist patients in achieving significant, sustainable results when paired with a balanced diet and lifestyle under medical supervision